Last reviewed · How we verify
long acting tolterodine 4 mg
long acting tolterodine 4 mg is a Small molecule drug developed by Mansoura University. It is currently in Phase 2 development.
At a glance
| Generic name | long acting tolterodine 4 mg |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (NA)
- Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder (PHASE2, PHASE3)
- Combined Behavioral and Drug Treatment of Overactive Bladder in Men (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- long acting tolterodine 4 mg CI brief — competitive landscape report
- long acting tolterodine 4 mg updates RSS · CI watch RSS
- Mansoura University portfolio CI
Frequently asked questions about long acting tolterodine 4 mg
What is long acting tolterodine 4 mg?
long acting tolterodine 4 mg is a Small molecule drug developed by Mansoura University.
Who makes long acting tolterodine 4 mg?
long acting tolterodine 4 mg is developed by Mansoura University (see full Mansoura University pipeline at /company/mansoura-university).
What development phase is long acting tolterodine 4 mg in?
long acting tolterodine 4 mg is in Phase 2.
Related
- Manufacturer: Mansoura University — full pipeline
- Compare: long acting tolterodine 4 mg vs similar drugs
- Pricing: long acting tolterodine 4 mg cost, discount & access